<DOC>
	<DOCNO>NCT00219557</DOCNO>
	<brief_summary>This Phase 2 study conduct multiple center United States , Europe Canada . Patients pancreatic cancer locally advance spread part body ( i.e. , metastatic ) eligible participate . Patients must prior systemic treatment advance disease . The purpose study test whether angiogenesis inhibitor Axitinib [ AG-013736 ] combination gemcitabine effective treatment advance pancreatic cancer vs. gemcitabine alone overall survival .</brief_summary>
	<brief_title>AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>patient advance ( localize surgically unresectable metastatic ) histologically/cytologically proven epithelial cancer exocrine pancreas prior therapy metastatic disease patient locally advanced disease candidate radiation therapy . uncontrolled brain metastasis ( control brain metastasis must previously treat , asymptomatic , without growth 4 month )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Randomized Phase 2 Study AG-013736 Combination Gemcitabine versus Gemcitabine Alone Advanced Pancreatic Cancer</keyword>
</DOC>